Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Risk and Volatility
Prelude Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.28, suggesting that its share price is 228% more volatile than the S&P 500.
Insider and Institutional Ownership
79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 1.5% of Curis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Prelude Therapeutics and Curis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prelude Therapeutics | $22.42 million | 11.89 | -$99.50 million | ($0.73) | -4.58 |
| Curis | $4.31 million | 0.41 | -$7.58 million | ($6.36) | -0.07 |
Curis has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Prelude Therapeutics and Curis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prelude Therapeutics | N/A | -75.35% | -44.39% |
| Curis | N/A | -639.43% | -213.05% |
Analyst Recommendations
This is a summary of current ratings and target prices for Prelude Therapeutics and Curis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prelude Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Curis | 1 | 1 | 1 | 0 | 2.00 |
Prelude Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 161.98%. Curis has a consensus target price of $43.00, suggesting a potential upside of 9,993.90%. Given Curis’ higher possible upside, analysts clearly believe Curis is more favorable than Prelude Therapeutics.
Summary
Prelude Therapeutics beats Curis on 9 of the 13 factors compared between the two stocks.
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.
About Curis
Curis, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation. Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
